Skip to content

Newsroom

Connect with trending topics, events, the industry's best thinkers, news and information.

03/26/2020

CarePort enables safe transitions of care during COVID-19 outbreak

Launches industry resource providing current learnings, latest trends and best practices from 1,000 hospitals and 180,000 post-acute providers are now available through CarePort’s COVID-19 Transitions of Care Hub

CHICAGO–(BUSINESS WIRE)–Mar. 26, 2020–
CarePort Health, a wholly-owned subsidiary of Allscripts (NASDAQ: MDRX) that connects 1,000 hospitals with 180,000 post-acute providers, is launching the COVID-19 Transitions of Care (“TOC”) Hub as an educational resource to share current learnings, latest trends and best practices for safe and effective transitions for COVID-19 patients across the healthcare system. Hospitals across the US send 18 million referrals annually through CarePort to skilled nursing, home health, hospice, long-term acute and acute rehabilitation, which accounts for nearly 40% of all acute to post-acute transitions nationally. Given that CarePort customers are on the front lines of the pandemic, the TOC Hub aims to disseminate critical lessons learned in real time.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200326005650/en/

“The COVID-19 pandemic presents unchartered territory for hospital and post-acute providers, and CarePort and Allscripts are supporting our partners’ most pressing needs in the fight against this disease,” said Allscripts Chief Executive Officer Paul Black. “Leveraging the largest network of connected acute and post-acute providers, CarePort technology is already being used on the front lines to support safe and efficient patient transitions during the COVID-19 outbreak.”

The following insights are currently highlighted in the COVID-19 Transitions of Care Hub:

More visibility on COVID-19 hospitalizations needed

In the Centers for Disease Control and Prevention’s March 18, 2020 Morbidity and Mortality Weekly Report, while 508 hospitalizations were reported, 1,514 cases were missing hospitalization status. Leveraging representative data from across CarePort’s customer base, CarePort analysis shows 777 confirmed COVID-19 diagnoses and an additional 3,726 suspected cases hospitalized last week alone. In an effort to provide more visibility to COVID-19 hospitalizations, CarePort will publish ongoing reports on COVID-19 trends across its acute and post-acute providers in 43 states.

Providers seek notifications on COVID-19 patients who may be diagnosed in outside hospitals

Hospitals may be aware of COVID-19 diagnoses at their own facilities, but patients often seek care at outside hospitals, and even across state lines. Given our national network of hospitals and post-acute providers, CarePort is enabling providers in our network to receive alerts when a patient with whom they had an encounter is diagnosed with COVID-19. As a best practice, real-time alerts are also being sent to the primary care physician so that they can ensure appropriate follow-up care.

Finding nursing homes for COVID-19 patients is creating bottlenecks in hospitals

In areas where there is an influx of COVID-19 patients, finding post-acute providers that are willing and able to accept COVID-19 patients has been a challenge. CarePort is working with hospitals to reduce bottlenecks on the discharge end by identifying post-acute providers that are accepting or are currently caring for COVID-19 patients. Post-acute providers are updating on a daily basis their capacity to accept COVID-19 patients. CarePort is also providing clients with a COVID-19 assessment created by a client partner for patients referred to nursing homes. Nursing homes can use this information to easily identify whether they are able to accept the patient.

Hospitals are leveraging ways to help patients choose nursing homes virtually

Hospitals are restricting visitors, including family members who often play an important role in helping patients select a nursing home or other post-acute provider. Nursing homes are also no longer allowing tours that would normally take place. In response, CarePort has enabled hospitals to share nursing home options with families via text message or email. Family members, who otherwise would be on-site, can see an interactive guide that includes virtual tours and pictures to help their loved ones select the right post-acute provider.

Given CarePort’s extensive access to robust acute and post-acute data across its national network of providers, the COVID-19 Transitions of Care Hub will continue to monitor trends and share follow-up observations with the hope that this serves as a valuable resource to ensure safe and effective transitions of care for COVID-19 patients.

Visit CarePort’s COVID-19 Transitions of Care Hub at www.CovidTOC.com for critical insights updated in real-time.

About CarePort

CarePort is the leading care coordination network with thousands of providers connected across the US. Care teams use CarePort to manage transitions in care, enable ED diversion and readmission reduction programs, and oversee post-acute cost and outcomes by tracking populations in real-time across the continuum. The end-to-end platform bridges acute and post-acute EHRs, providing visibility and actionable intelligence so that providers and payers can efficiently and effectively coordinate patient care. Follow us on LinkedIn and Twitter.

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2020 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Concetta Rasiarmos

312-447-2466

concetta.rasiarmos@allscripts.com

Source: Allscripts

03/18/2020

Allscripts response to the COVID-19 outbreak

Company takes additional actions to protect associates, clients and partners against COVID-19

CHICAGO–(BUSINESS WIRE)–
Allscripts (NASDAQ: MDRX) is taking several steps to further its commitment to help fight the global spread of COVID-19. The company is working closely with health agencies and governments around the world to keep abreast of changes and partnering with clients to share and enable their Allscripts solutions to help combat the spread of the virus and manage their patients.

Allscripts has made updates across each of its electronic health record solutions; one example is updating clinical decision support tools in its EHRs with the most current screening tools and CDC recommendations. Allscripts also offers specific solutions that can help providers fight the spread of COVID-19, including FollowMyHealth® Telehealth, Allscripts Virtual Triage and IT Service staffing to supplement clients’ teams.

FollowMyHealth to offer streamlined telehealth implementation

Allscripts has created a specialized plan for clients to swiftly implement telehealth at their organizations through its EHR-agnostic patient engagement platform, FollowMyHealth. This expedited implementation includes a step-by-step client decision workbook, 10 remote project hours for training and set up and specialized COVID-19 form and alert verbiage for patient outreach, enabling clients to be up and running in a matter of days. The FollowMyHealth solution is in line with recommendations made by the CDC to proactively reach out to patients prior to appointments and explore alternatives to face-to-face triage and visits. By converting appointments to telehealth, the solution can help limit no-shows and cancellations while delivering care to those who need it.

Allscripts Virtual Triage solution to provide much needed support for organizations

Allscripts Virtual Triage is an EHR-agnostic, automated triage tool with CDC-defined screening measures built in to address immediate concerns regarding identification and prompt treatment of specific diseases, including screening outreach for COVID-19. There is no prior healthcare organization registration relationship required for patients to use the online app. Allscripts Virtual Triage will screen patients into four categories: no further intervention needed, a virtual telehealth on-demand waiting room, a follow-up queue for email or phone callback, or location of nearest COVID-19 testing facility. The solution acts to ensure depleted resources within an organization are targeted to the most at-risk population. Allscripts Virtual Triage can be implemented in just a few days.

Workforce Planning

Allscripts has created processes to ensure its support and services teams are fully staffed. Employees are equipped to work remotely, with the full capabilities available in all company facilities. Allscripts also has great flexibility of staff around the globe, enabling the company to pivot resources as needed to adapt to the evolving crisis.

To help protect the health and safety of Allscripts associates, clients and partners, the company has taken action to prevent additional spread of the virus by implementing strict travel restrictions for employees and converting many scheduled client meetings to virtual briefings.

All Allscripts-hosted large events and gatherings have been postponed or canceled. In addition, the company has implemented a work-from-home policy for associates, further strengthened our IT infrastructure and taken advanced steps in ensuring our facilities are cleaned and operating in accordance with CDC and WHO guidelines. Essential travel, including travel to client sites, continues when required to ensure the continuity of Allscripts’ mission-critical solutions.

“The spread of COVID-19 is putting a significant strain on our country’s healthcare system, as everyone on the front lines is working incredibly hard to combat the disease,” said Allscripts Chief Executive Officer Paul Black. “In partnering with our clients to fight the virus’ spread, new telehealth capabilities and supplemental IT staffing resources will be incredibly important. We’re proud to stand beside our clients as we fight this global threat and unprecedented challenge for 21st-century healthcare delivery.”

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2020 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Concetta Rasiarmos

312-447-2466

concetta.rasiarmos@allscripts.com

Source: Allscripts

03/12/2020

Allscripts announces full support of HHS’ commitment to patients with final interoperability rules

CHICAGO–(BUSINESS WIRE)–
Allscripts Healthcare Solutions (NASDAQ: MDRX) announced today its support for the two transformative regulations recently released by the U.S. Department of Health and Human Services’ (HHS), believing both will move patients to the center of making their own health decisions, addressing the current obstacles with the flow of health information.

Allscripts has strongly advocated for policy efforts to address information blocking since they were first conceived in Congress and applauds the numerous opportunities for stakeholders to provide input through the HHS rule review process. Issued by the HHS Office of the National Coordinator for Health Information Technology (ONC) and Centers for Medicare & Medicaid Services (CMS), the two rules implement in more detail the interoperability and patient access provisions of the bipartisan 21st Century Cures Act (Cures Act).

Allscripts assists patients (and our clients in serving those patients) with open platforms that enable management of all personal health data, whether through the FollowMyHealth® personal health record, our interoperability and population health solution, dbMotion™, 2bPrecise, which facilitates the flow of critical genomic and genetic data, or the largest group of third-party API developers in the industry. These tested solutions, coupled with our electronic health record solutions, are running at scale: in small, independent physician practices; multi-specialty clinics, large IDNs, community hospitals in urban and rural environments; and even across entire countries. All are available and exchanging information today.

“Allscripts solutions and services are built on the principle that patient information belongs to and should be consented by the patient, and we created an EHR-agnostic, open architecture and culture in 2007—13 years ago,” said Allscripts Chief Executive Officer, Paul Black. “Interoperability of all data – to and from clinicians, patients and other appropriate stakeholders – has been our top priority for more than a decade, and we’ve conducted extensive work to build connections to researchers and payers in recent years. We applaud the work that HHS finished this month to directly address obstacles to health information data liquidity and maximize the entire system’s ability to continue progress toward improving outcomes and decreasing costs. The patients are counting on us all, and we believe that the healthcare ecosystem should be Open, For Everyone™. Allscripts is all in.”

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2020 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

For more information contact:

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Concetta Rasiarmos

312-447-2466

concetta.rasiarmos@allscripts.com

Source: Allscripts Healthcare Solutions

03/12/2020

Veradigm RxTruePrice Helps Drive Higher Medication Adherence

Allscripts business unit addresses need for better patient medication adherence through pricing transparency

CHICAGO–(BUSINESS WIRE)–
Allscripts Healthcare Solutions (NASDAQ: MDRX) and its payer and life science business unit, Veradigm™, announced its findings on the impact of Veradigm’s RxTruePrice™, a solution designed to address patient challenges resulting in them foregoing, discontinuing or substituting their prescribed medication due to cost and a lack of prescription drug price transparency.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200312005092/en/

Recent studies have revealed alarming statistics surrounding low medication adherence. For example, 33% of patients have purposely missed filling a prescription due to its prohibitive cost.1 And nearly 6% of patients have skipped taking their medications three times or more.1

Patient outcomes may improve if it were easier to ensure patients stay on their prescribed medication regimen by knowing the cost before they leave their doctor’s office. Higher out-of-pocket cost of prescription medications have been shown to correlate with increased prescribed prescription abandonment. With patients incurring a higher share of their healthcare costs, Veradigm’s RxTruePrice can help the 42% of Americans, who have reported they are struggling to pay for their necessary medication, gain a clearer view into pricing. 1

A recent Veradigm fielded study found that six out of ten RxTruePrice users have observed an overall improvement in patient prescription medication adherence since launching the solution.2 Users also felt that the availability of pricing data within their regular workflow held the potential to help them improve medication adherence as compared to alternate solutions, such as sponsored patient support programs and patient reminders.2

Used by tens of thousands of providers for tens of millions of price transparency transactions, Veradigm RxTruePrice provides users access to discounted health plan or pharmacy-benefit pricing, cash pricing, therapeutic alternatives and competitive prices at local and mail-order pharmacies. Further, all information is specific to each individual patient and is accessible in the provider’s e-prescribing workflow.

“Everyone knows healthcare costs are rising and people’s incomes can’t always keep up,” says RxTruePrice client Dr. Darla Kincaid of MD Pediatric Associates, in Coppell, TX. “Having that patient’s drug pricing information right there in the EHR, it makes for a phenomenal tool. It has helped us improve medication adherence as a practice, but just as importantly, it helps us better engage our patients. By demonstrating we share their concerns on cost of care, it makes us a team, and that is the goal.”

“Veradigm RxTruePrice is positioned to help bridge the gaps created by pharmaceutical companies’ pricing structures and positive patient outcomes,” said Veradigm CEO Tom Langan, “medication adherence is not a new problem, but now, it is a problem with a solution.”

Learn more about the impact of Veradigm RxTruePrice solution here.

1. Hamm, N. Managed Healthcare Executive. How High Drug Prices Affect Patients. May 2019. Available at https://www.managedhealthcareexecutive.com/drug-price/how-high-drug-prices-affect-patients

2. Results of Veradigm ePrescribe user survey conducted September 2019. Data on File.

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2020 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

For more information contact:

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Concetta Rasiarmos

312-447-2466

concetta.rasiarmos@allscripts.com

Source: Allscripts Healthcare Solutions

03/04/2020

Allscripts announces Veradigm AccelRx™ to help reduce patient wait times for specialty medications

Solution simplifies complex path to Rx fulfillment

CHICAGO–(BUSINESS WIRE)–
Allscripts Healthcare Solutions (NASDAQ:MDRX) has unveiled a unique new software solution for specialty medication management, delivered by Veradigm™, its business unit focused on payer and life sciences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200304005064/en/

Veradigm’s AccelRx™ is designed to simplify meeting the requirements needed to dispense the increasing number of specialty medications being prescribed. AccelRx leverages broad industry partnerships built over decades of e-prescribing and prior authorization to deliver a user-friendly solution that is helping providers spend less time on phone calls and managing faxes while driving higher patient medication adherence.

Despite representing only 3% of all prescriptions written in the U.S., in 2020, specialty medications are expected to account for up to 50% of the total spend on prescription medications. For a specialty medication prescription to be filled, it must pass through a broad cross-section of healthcare stakeholders, including payers, specialty pharmacies and specialty Rx hubs. The result can be extended patient wait times.

“AccelRx is another example of Veradigm spanning the healthcare ecosystem to find mutually beneficial ways for key stakeholders to work together and to improve patient care,” said Tom Langan, CEO of Veradigm. “By delivering a solution that can automate and simplify the complex series of reviews required to fill a specialty prescription, we believe we can help a broad group of healthcare providers to reduce the time it takes to get these medications to patients.”

Combining one of healthcare’s largest prescriber bases with broad industry partnerships built over decades of e-prescribing and prior authorization leadership, Veradigm AccelRx delivers a solution designed to streamline specialty medication fulfillment and reduce patient wait times.

“There is a growing number of patients affected by the extended delays in receiving their prescribed specialty medications, and it’s a challenge for many segments of the healthcare market including patients and providers,” said Paul Black, Allscripts Chief Executive Officer. “That’s why it is so important to be part of the solution to address this growing need.”

As the impact of specialty medications on healthcare in the U.S. continues to grow, so does the number of patients and providers who can benefit from the value AccelRx provides. As a result, Veradigm is actively engaged in developing ongoing partnerships with key healthcare industry stakeholders to continue expanding the scope of sophistication of the AccelRx solution throughout 2020 and beyond. For more information, visit www.veradigm.com/accelrx.

About Veradigm™

Veradigm is an integrated data systems and services company that combines data-driven clinical insights with actionable tools to help healthcare stakeholders improve the quality, efficiency, and value of healthcare delivery— including biopharma, health plans, healthcare providers, health technology partners, and most importantly, the patients they serve. We are dedicated to simplifying the complicated healthcare system with next-generation healthcare solutions. This is how we are transforming health, insightfully. To learn more, visit www.veradigmhealth.com.

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2020 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

For more information contact:

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Concetta Rasiarmos

312-447-2466

concetta.rasiarmos@allscripts.com

Source: Allscripts

03/02/2020

Allscripts announces fourth quarter 2019 results and outlook for 2020
  • Fourth quarter 2019 bookings of $312 million, up 6% year-over-year
  • Extended Allscripts Managed Services Agreement with Northwell Health through 2026
  • Contract revenue backlog up $500 million to $4.4 billion as of the end of the fourth quarter

CHICAGO–(BUSINESS WIRE)–
Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (Allscripts) announced its financial results for the three and twelve months ended December 31, 2019.

Bookings(1) were $312 million in the fourth quarter of 2019. This result compares with $295 million in the fourth quarter of 2018. Contract revenue backlog totaled $4.4 billion as of December 31, 2019.

Fourth quarter 2019 GAAP revenue was $451 million compared with $442 million in the fourth quarter of 2018. Fourth quarter 2019 non-GAAP revenue totaled $452 million compared with $441 million in the fourth quarter of 2018.

On a GAAP basis in the fourth quarter of 2019 and 2018, total operating expenses were $215 million. Non-GAAP operating expenses totaled $148 million compared with $154 million in the fourth quarter of 2018.

GAAP net loss in the fourth quarter of 2019 totaled $19 million compared with net income of $375 million in the fourth quarter of 2018. Non-GAAP net income in the fourth quarter of 2019 totaled $28 million compared with $33 million in the fourth quarter of 2018.

GAAP loss per share in the fourth quarter of 2019 was $0.12 compared with earnings per share of $2.14 in the fourth quarter of 2018. Non-GAAP diluted earnings per share in the fourth quarter of 2019 were $0.17 compared with $0.18 in the fourth quarter of 2018.

Adjusted EBITDA in the fourth quarter of 2019 and 2018 totaled $74 million.

“Our fourth quarter results show continued strength in new bookings which positions us well for growth across our platforms,” commented Paul M. Black, Chief Executive Officer of Allscripts. “We announced a number of key client extensions, including managed services at Northwell Health, that demonstrate our strong positioning in the marketplace. Looking ahead, we believe we have positioned Allscripts to benefit from the investments we have made to expand the company’s portfolio outside the EHR while maintaining a disciplined cost structure.”

Leadership Change

Allscripts also announced that Rick Poulton has been named President and Chief Financial Officer of the company, effective March 3, 2020. Mr. Poulton will be replacing Dennis Olis, who will be leaving the company. Mr. Poulton previously served as the company’s Chief Financial Officer from October 2012 through March 2016.

2020 Financial Outlook(2)

Allscripts currently expects to achieve:

  • Full year 2020 bookings (1) between $900 million and $1,000 million
  • Full year 2020 revenue between $1,750 million and $1,850 million
  • Full year 2020 non-GAAP earnings per share between $0.70 and $0.75
  • First quarter 2020 bookings(1) between $175 million and $200 million
  • First quarter 2020 revenue between $420 million and $430 million

Conference Call

Allscripts will conduct a conference call today, Monday, March 2nd, 2020, at 4:30 PM Eastern Time to discuss its earnings release and other information. Participants may access the conference call via webcast at http://investor.allscripts.com. Participants also may access the conference call by dialing +1 (877) 269-7756 or +1 (201) 689-7817 (international) and requesting Conference ID # 13699139.

A replay of the call will be available approximately two hours after the conclusion of the call, for a period of four weeks, on the Allscripts Investor Relations website or by calling +1 (877) 660-6853 or +1 (201) 612-7415 – Conference ID # 13699139.

Supplemental and non-GAAP financial information is also available at http://investor.allscripts.com.

Footnotes

  1. Bookings have been determined on a continuing operations basis, excluding Netsmart, and reflect the value of executed contracts for software, hardware, client services, private cloud hosting services, outsourcing and other subscription-based services.
  2. In providing financial guidance, the company does not reconcile non-GAAP earnings per share and non-GAAP revenue guidance to the corresponding GAAP financial measures. Allscripts does not provide guidance for the various reconciling items since certain items that impact GAAP net income and GAAP revenue such as acquisition-related deferred revenue adjustments, acquisition-related amortization, asset impairment charges and transaction, legal and other costs, any of which may be significant, are either outside of its control and/or cannot be reasonably predicted. Please see the “Explanation of Non-GAAP Financial Measures” at the end of this press release for detailed information on calculating non-GAAP measures. For a reconciliation of other non-GAAP items, see the non-GAAP financial reconciliation tables in this release (Tables 4, 5, 6 and 7).

NOTE: All percentage changes described within this press release are calculated from full dollar amounts as illustrated in the accompanying financial statements and Allscripts Supplemental Financial Data Workbook, posted on the Investor Relations website. Rounding differences may occur when individually calculating percentages or totals from rounded amounts included within the press release body compared to full dollar amounts in the tables.

About Allscripts

Allscripts (Nasdaq: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2020 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including the statements under “2020 Financial Outlook” and statements related to expected benefits of strategic partnerships and investments. These forward-looking statements are based on the current beliefs and expectations of Allscripts management, only speak as of the date that they are made and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “can,” “may,” and similar terms. Actual results could differ significantly from those set forth in the forward-looking statements and reported results should not be considered an indication of future performance. Certain factors that could cause Allscripts actual results to differ materially from those described in the forward-looking statements include, but are not limited to: failure by Practice Fusion to comply with the terms of its settlement agreements with the U.S. Department of Justice (the “DOJ”); the costs and burdens of compliance by Practice Fusion with the terms of its settlement agreements with the DOJ; potential additional investigations and proceedings from governmental entities or third parties other than the DOJ related to the same or similar conduct underlying the DOJ’s investigations into Practice Fusion’s business practices; the expected financial results of businesses acquired by us, including the EIS business, the NantHealth provider/patient solutions business, Practice Fusion and HealthGrid; the successful integration of businesses recently acquired by us; the anticipated and unanticipated expenses and liabilities related to the EIS business, the NantHealth provider/patient solutions business, Practice Fusion and HealthGrid, including the civil investigation by the U.S. Attorney’s Office involving our EIS business; security breaches resulting in unauthorized access to our or our clients’ computer systems or data, including denial-of-services, ransomware or other Internet-based attacks; Allscripts failure to compete successfully; consolidation in Allscripts industry; current and future laws, regulations and industry initiatives; increased government involvement in Allscripts industry; the failure of markets in which Allscripts operates to develop as quickly as expected; Allscripts or its customers’ failure to see the benefits of government programs; changes in interoperability or other regulatory standards; the effects of the realignment of Allscripts sales, services and support organizations; market acceptance of Allscripts products and services; the unpredictability of the sales and implementation cycles for Allscripts products and services; Allscripts ability to manage future growth; Allscripts ability to introduce new products and services; Allscripts ability to establish and maintain strategic relationships; risks related to the acquisition of new businesses or technologies; the performance of Allscripts products; Allscripts ability to protect its intellectual property rights; the outcome of legal proceedings involving Allscripts; Allscripts ability to hire, retain and motivate key personnel; performance by Allscripts content and service providers; liability for use of content; price reductions; Allscripts ability to license and integrate third party technologies; Allscripts ability to maintain or expand its business with existing customers; risks related to international operations; changes in tax rates or laws; business disruptions; Allscripts ability to maintain proper and effective internal controls; and asset and long-term investment impairment charges. Additional information about these and other risks, uncertainties, and factors affecting Allscripts business is contained in Allscripts filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in the most recent Allscripts Annual Report on Form 10-K and subsequent Form 10-Qs. Allscripts does not undertake to update forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes in its business, financial condition or operating results over time.

Table 1
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Balance Sheets
(In millions)
(Unaudited)
 

December 31,

 

December 31,

2019

 

2018

ASSETS
Current assets:
Cash and cash equivalents

$129.6

$174.2

Restricted cash

7.9

10.6

Accounts receivable, net

459.8

465.3

Contract assets

96.0

66.4

Prepaid expenses and other current assets

148.0

142.5

Total current assets

841.3

859.0

Fixed assets, net

88.3

121.9

Software development costs, net

243.9

209.7

Intangible assets, net

374.1

431.1

Goodwill

1,362.0

1,373.7

Deferred taxes, net

5.7

5.0

Contract assets – long-term

67.6

71.9

Right-of-use assets – operating leases

98.0

0.0

Other assets

124.8

109.2

Total assets

$3,205.7

$3,181.5

 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable

$104.0

$73.2

Accrued expenses

270.7

107.0

Accrued compensation and benefits

68.6

100.1

Income tax payable

0.0

29.6

Deferred revenue

379.8

466.8

Current maturities of long-term debt

364.5

20.1

Current operating lease liabilities

23.1

0.0

Current liabilities attributable to discontinued operations

0.0

0.9

Total current liabilities

1,210.7

797.7

Long-term debt

551.0

647.5

Deferred revenue

12.3

16.0

Deferred taxes, net

21.0

58.5

Long-term operating lease liabilities

95.2

0.0

Other liabilities

30.3

81.4

Total liabilities

1,920.5

1,601.1

Total Allscripts Healthcare Solutions, Inc.’s stockholders’ equity

1,285.2

1,551.1

Non-controlling interest

0.0

29.3

Total stockholders’ equity

1,285.2

1,580.4

Total liabilities and stockholders’ equity

$3,205.7

$3,181.5

Table 2
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Statements of Operations
(In millions, except per share amounts)
(Unaudited)
 

Three Months Ended December 31,

 

Twelve Months Ended December 31,

2019

 

2018

 

2019

 

2018

Revenue:
Software delivery, support and maintenance

$281.6

$289.1

$1,126.5

$1,128.3

Client services

169.4

153.2

645.2

621.7

Total revenue

451.0

442.3

1,771.7

1,750.0

Cost of revenue:
Software delivery, support and maintenance

89.1

91.2

359.0

357.0

Client services

152.3

136.1

583.1

565.5

Amortization of software development and acquisition-related assets (a)

29.5

26.9

116.0

102.9

Total cost of revenue

270.9

254.2

1,058.1

1,025.4

Gross profit

180.1

188.1

713.6

724.6

Selling, general and administrative expenses

112.9

100.0

419.8

451.0

Research and development

62.9

66.1

254.5

268.4

Asset impairment charges

6.8

28.1

10.8

58.2

Goodwill impairment charge

25.7

13.5

25.7

13.5

Amortization of intangible and acquisition-related assets

6.8

7.0

27.2

26.6

Income (loss) from operations

(35.0)

(26.6)

(24.4)

(93.1)

Interest expense and other, net (b)

(7.0)

(13.3)

(182.1)

(50.9)

Gain (loss) on sale of business, net

0.0

0.0

0.0

172.3

Recovery (impairment) on long-term investments

(1.7)

0.0

(0.7)

(15.5)

Equity in net income (loss) of unconsolidated investments

0.2

(0.1)

0.7

0.3

Income (loss) before income taxes

(43.5)

(40.0)

(206.5)

13.1

Income tax (provision) benefit

24.5

5.4

23.9

(0.4)

Income (loss) from continuing operations, net of tax

(19.0)

(34.6)

(182.6)

12.7

Income (loss) from discontinued operations

0.0

(39.9)

0.0

(72.8)

Gain on sale of Netsmart

0.0

500.4

0.0

500.4

Income tax effect on discontinued operations

0.0

(40.0)

0.0

(32.5)

Income (loss) from discontinued operations, net of tax

0.0

420.5

0.0

395.1

Net income (loss)

(19.0)

385.9

(182.6)

407.8

Net (income) loss attributable to non-controlling interest

0.0

1.0

0.4

4.5

Accretion of redemption preference on redeemable convertible
non-controlling interest – discontinued operations

0.0

(12.2)

0.0

(48.6)

Net Income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders

($19.0)

$374.7

($182.2)

$363.7

 
Income (loss) from continuing operations per share – basic

($0.12)

($0.19)

($1.10)

$0.10

Income (loss) from discontinued operations per share – basic

$0.00

$2.36

$0.00

$1.97

Income (loss) earnings per share – basic

($0.12)

$2.17

($1.10)

$2.07

 
Income (loss) from continuing operations per share – diluted

($0.12)

($0.19)

($1.10)

$0.10

Income (loss) from discontinued operations per share – diluted

$0.00

$2.33

$0.00

$1.94

Income (loss) earnings per share – diluted

($0.12)

$2.14

($1.10)

$2.04

 
Weighted average common shares outstanding:
Basic

162.4

173.4

166.3

176.0

Diluted

162.4

175.4

166.3

178.5

 

Three Months Ended December 31,

 

Twelve Months Ended December 31,

2019

 

2018

 

2019

 

2018

 
(a) Amortization of software development and acquisition-related assets includes:
Amortization of capitalized software development costs

$20.2

$17.4

$79.5

$64.4

Amortization of acquisition-related intangible assets

9.3

9.5

36.5

38.5

Total amortization of software development and acquisition-related assets

$29.5

$26.9

$116.0

$102.9

 
(b) Interest expense and other, net are comprised of the following for the periods presented:
 
Non-cash charges to interest expense

$3.7

$3.2

13.7

$12.7

Interest expense

7.3

9.9

26.6

35.3

Amortization of discounts and debt issuance costs

0.8

0.8

2.9

2.9

Other (income) loss, net

(4.8)

(0.6)

138.9

0.0

Total interest expense and other, net

$7.0

$13.3

$182.1

$50.9

 
Table 3
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Statements of Cash Flows
(In millions)
(Unaudited)
 

Three Months Ended

December 31,

 

Twelve Months Ended

December 31,

2019

 

2018

 

2019

 

2018

Cash flows from operating activities:
Net income (loss)

($19.0)

$385.9

($182.6)

$407.8

Less: Income(loss) from discontinued operations

0.0

420.5

0.0

395.1

Income (loss) from continuing operations

($19.0)

($34.6)

($182.6)

$12.7

Non-cash adjustments to net income (loss):
Depreciation and amortization

54.8

49.3

207.1

192.3

Operating right-to-use asset amortization

5.8

0.0

22.5

0.0

Stock-based compensation expense

9.4

8.8

39.0

34.6

Asset impairment charges

6.8

28.1

10.8

58.2

Goodwill impairment

25.7

13.5

25.7

13.5

Impairment (recovery) of long-term investments

1.7

0.0

0.7

15.5

(Gain) loss on sale of businesses, net

0.0

0.0

0.0

(172.3)

Other, net

(27.5)

(9.8)

(28.5)

(5.2)

Total non-cash adjustments to net income (loss)

76.7

89.9

277.3

136.6

Cash impact of changes in operating assets and liabilities

(45.3)

(31.3)

(18.4)

(60.1)

Net cash provided by (used in) operating activities – continuing operations

12.4

24.0

76.3

89.2

Net cash provided by (used in) operating activities – discontinued operations

0.0

(37.6)

(30.0)

(21.3)

Net cash provide by (used in) operating activities

12.4

(13.6)

46.3

67.9

Cash flows from investing activities:
Capital expenditures

(3.1)

(9.4)

(16.6)

(31.3)

Capitalized software

(27.7)

(30.2)

(113.9)

(113.3)

Purchases of equity securities in partner entities, business
acquisitions, net of cash acquired and other investments

0.0

(14.2)

(30.6)

(194.2)

Cash received from sale of businesses, net

0.0

566.6

0.0

807.8

Net cash provided by (used in) investing activities – continuing
operations

(30.8)

512.8

(161.1)

469.0

Net cash provided by (used in) investing activities – discontinued – operations

0.0

(31.5)

0.0

(221.0)

Net cash provided by (used in) investing activities

(30.8)

481.3

(161.1)

248.0

Cash flows from financing activities:
Repurchase of common stock

0.0

(37.0)

(111.5)

(138.9)

Proceeds from sale or issuance of common stock

0.0

0.0

0.0

1.3

Stock-based compensation-related payments, net

(0.5)

(0.7)

(7.3)

(9.5)

Proceeds from the issuance of 0.875% Notes

218.0

0.0

218.0

0.0

Payments for issuance costs on 0.875% Convertible Senior Notes

(5.4)

0.0

(5.4)

0.0

Payments for capped call transactions on 0.875% Convertible Senior Notes

(17.2)

0.0

(17.2)

0.0

Credit facilities and capital lease payments, net

(174.9)

(359.0)

59.2

(283.5)

Other payments

(3.1)

(1.6)

(68.5)

(11.8)

Net cash provided by (used in) financing activities – continuing operations

16.9

(398.3)

67.3

(442.4)

Net cash provided by (used in) financing activities – discontinued operations

0.0

(4.1)

0.0

149.4

Net cash provided by (used in) financing activities

16.9

(402.4)

67.3

(293.0)

Effect of exchange rate changes on cash and cash equivalents

0.3

(0.3)

0.2

(0.6)

Net increase (decrease) in cash and cash equivalents

(1.2)

65.0

(47.3)

22.3

Cash and cash equivalents, beginning of period

138.7

119.8

184.8

162.5

Cash and cash equivalents, end of period

$137.5

$184.8

$137.5

$184.8

Table 4
Allscripts Healthcare Solutions, Inc.
Condensed Non-GAAP Financial Information
(In millions, except per share amounts)
(Unaudited)
 

Three Months Ended December 31, 2019

 

Three Months Ended December 31, 2018

GAAP

 

Non-GAAP

Adjustments (1)

 

Non-GAAP

 

GAAP

 

Non-GAAP

Adjustments (1)

 

Non-GAAP

 
Revenue

$451.0

$0.5

$451.5

$442.3

($1.4)

$440.9

Gross profit

180.1

11.8

191.9

188.1

11.7

199.8

Total Operating Expenses

215.1

(67.1)

148.0

214.7

(60.4)

154.3

Income (loss) from operations

(35.0)

78.9

43.9

(26.6)

72.1

45.5

Income (loss) from continuing operations, net of tax, net of non-controlling interest

($19.0)

$47.0

$28.0

($33.6)

$66.1

$32.5

 
Income (loss) from continuing operations per share – diluted

($0.12)

$0.17

($0.19)

$0.18

 
Effective Tax Rate

56%

24%

14%

10%

 
Weighted average common shares outstanding – diluted

162.4

164.9

175.4

175.4

 
 
Twelve Months Ended December 31, 2019 Twelve Months Ended December 31, 2018
GAAP Non-GAAP
Adjustments (1)
Non-GAAP GAAP Non-GAAP
Adjustments (1)
Non-GAAP
 
Revenue

$1,771.7

$2.0

$1,773.7

$1,750.0

$15.2

$1,765.2

Gross profit

713.6

53.2

766.8

724.6

83.2

807.8

Total Operating Expenses

738.0

(145.7)

592.3

817.7

(199.7)

618.0

Income (loss) from operations

(24.4)

198.9

174.5

(93.1)

282.9

189.8

Income (loss) from continuing operations, net of tax, net of non-controlling interest

($182.2)

$294.2

$112.0

$17.2

$104.7

$121.9

 
Income (loss) from continuing operations per share – diluted

($1.10)

$0.67

$0.10

$0.68

 
Effective Tax Rate

12%

24%

3%

23%

 
Weighted average common shares outstanding – diluted

166.3

168.1

178.5

178.5

 
 
(1) Please see table 6 for detail on Non-GAAP adjustments.
Table 5
Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information – Adjusted EBITDA
(In millions, except percentages)
(Unaudited)
 

Three Months Ended December 31,

 

Twelve Months Ended December 31,

2019

 

2018

 

2019

 

2018

Net income (loss) from continuing operations, as reported

($19.0)

($34.6)

($182.6)

$12.7

Plus:
Interest expense and other, net (a)

7.3

9.3

25.3

35.3

Depreciation and amortization

54.8

49.3

207.1

192.3

Equity in net (income) loss of unconsolidated investments

(0.2)

0.1

(0.7)

(0.3)

Tax provision/(benefit)

(24.5)

(5.4)

(23.9)

0.4

EBITDA

$18.4

$18.7

$25.2

$240.4

Plus:
Acquisition-related deferred revenue adjustments

0.5

0.9

2.0

24.3

Stock-based compensation expense

10.1

9.4

42.6

39.3

Transaction, legal and other costs

10.6

3.4

188.1

82.3

Asset impairment charges

6.8

28.1

10.8

58.2

Goodwill impairment charges

25.7

13.5

25.7

13.5

(Recovery) impairment on long-term investments

1.7

0.0

0.7

15.5

(Gain) loss on sale of business, net

0.0

0.0

0.0

(172.3)

Adjusted EBITDA

$73.8

$74.0

$295.1

$301.2

 

Adjusted EBITDA margin (b)

16%

17%

17%

17%

 
 
(a) Interest expense and other, net has been adjusted from the amounts presented in the statements of operations in order to remove the amortization of the fair value of the cash conversion option embedded in the 1.25% and .875% Cash Convertible Notes and deferred debt issuance costs from interest expense since such amortization is also included in depreciation and amortization.
 
(b) Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by non-GAAP revenue.
Table 6
Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information – Non-GAAP Adjustments
(In millions, except percentages)
(Unaudited)
 
 

Three Months Ended December 31,

 

Twelve Months Ended December 31,

2019

 

2018

 

2019

 

2018

 
Income (loss) from continuing operations, net of tax and net of non-controlling interest

($19.0)

($33.6)

($182.2)

$17.2

Acquisition-related deferred revenue adjustments

0.5

0.9

2.0

24.3

Revenue

0.5

(1.4)

2.0

15.2

Gross Profit

0.5

0.9

2.0

24.3

Income (loss) from operations

0.5

0.9

2.0

24.3

Acquisition-related amortization

16.1

16.5

63.7

65.1

Gross Profit

9.3

9.5

36.5

38.5

Income (loss) from operations

16.1

16.5

63.7

65.1

Stock-based compensation expense

10.1

9.4

42.6

39.3

Gross Profit

1.6

1.1

6.1

6.2

Income (loss) from operations

10.1

9.4

42.6

39.3

Asset impairment charges

6.8

28.1

10.8

58.2

Income (loss) from operations

6.8

28.1

10.8

58.2

Goodwill impairment charges

25.7

13.5

25.7

13.5

Income (loss) from operations

25.7

13.5

25.7

13.5

Transaction, legal and other costs

15.9

3.5

195.2

82.3

Gross Profit

0.4

0.2

8.6

14.2

Income (loss) from operations

19.7

3.7

54.1

82.5

Income (loss) from continuing operations before income taxes

15.9

3.5

195.2

82.3

Non-cash charges to interest expense and other

3.7

3.6

13.7

14.6

(Recovery) impairment on long-term investments

1.7

0.0

0.7

15.5

(Gain) loss on sale of business, net

0.0

0.0

0.0

(172.3)

Equity in net (income) loss of unconsolidated investments

(0.2)

0.1

(0.7)

(0.3)

Tax rate alignment

(33.3)

(8.9)

(59.2)

(34.9)

Net (income) loss attributable to non-controlling interest

(0.0)

(0.6)

(0.3)

(0.6)

Non-GAAP income (loss) attributable to Allscripts Healthcare Solutions, Inc.

$28.0

$32.5

$112.0

$121.9

 
Non-GAAP effective tax rate

24%

10%

24%

23%

 
Weighted average shares outstanding – diluted

164.9

175.4

168.1

178.5

Table 7
Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information – Free Cash Flow
(In millions)
(Unaudited)
 

Three Months Ended December 31,

 

Twelve Months Ended December 31,

2019

 

2018

 

2019

 

2018

Net cash provided by (used in) operating activities – continuing operations

$12.4

$24.0

$76.3

$89.2

Net cash provided by (used in) operating activities – discontinued operations

0.0

(37.6)

(30.0)

(21.3)

Net cash provided by (used in) operating activities

12.4

(13.6)

46.3

67.9

Cash flows from investing activities:
Capital expenditures

(3.1)

(9.4)

(16.6)

(31.3)

Capitalized software

(27.7)

(30.2)

(113.9)

(113.3)

Cash flows from investing activities – discontinued operations

0.0

(8.6)

0.0

(31.5)

Free cash flow

($18.4)

($61.8)

($84.2)

($108.2)

Explanation of Non-GAAP Financial Measures

Allscripts reports its financial results in accordance with U.S. generally accepted accounting principles, or GAAP. To supplement this information, Allscripts presents in this release non-GAAP revenue, gross profit, gross margin, operating expense, income from operations, Adjusted EBITDA, effective income tax rate, net income, earnings per share and free cash flow, which are considered non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. The definitions of non-GAAP financial measures used throughout this document are presented below:

  • Non-GAAP revenue consists of GAAP revenue, as reported, and adds back recognized deferred revenue from the EIS business, Practice Fusion, HealthGrid, NantHealth’s provider/patient solutions business and non-material consolidated affiliates that is eliminated for GAAP purposes due to purchase accounting adjustments. Reconciliations to GAAP revenue are found in Tables 4 and 6 within this press release.
  • Non-GAAP gross profit consists of GAAP gross profit, as reported, and excludes acquisition-related deferred revenue adjustments, acquisition-related amortization, stock-based compensation expense, non-cash asset impairment charges and transaction, legal and other costs. Non-GAAP gross margin consists of non-GAAP gross profit as a percentage of non-GAAP revenue in the applicable period. Reconciliations to GAAP gross profit are found in Tables 4 and 6 within this press release.
  • Non-GAAP operating expense consists of GAAP selling, general and administrative expenses (SG&A) and research and development expense (R&D), as reported, and excludes transaction, legal and other costs and stock-based compensation expense recorded to SG&A and R&D. Reconciliations to GAAP operating expense are found in Table 4 within this press release.
  • Non-GAAP income from operations consists of GAAP income from operations, as reported, and excludes acquisition-related deferred revenue adjustments, acquisition-related amortization, stock-based compensation expense, non-cash asset impairment charges, goodwill impairment charges and transaction, legal and other costs. Reconciliations to GAAP income from operations are found in Tables 4 and 6 within this press release.
  • Adjusted EBITDA is a non-GAAP measure and consists of GAAP net income/(loss), as reported, and adjusts for: acquisition-related deferred revenue adjustments; depreciation and amortization; stock-based compensation expense; transaction, legal and other costs; non-cash asset and long-term investment impairment charges; goodwill impairment charges; gain on sale of businesses, net; interest expense and other, net; equity in net earnings of unconsolidated investments; and tax provision (benefit). Reconciliations to GAAP net income/(loss) are found in Table 5 within this press release.
  • Non-GAAP effective income tax rate is based on non-GAAP pre-tax earnings and consists of the statutory federal income tax rate, Allscripts effective state income tax rate and adjustments for permanent differences.
  • Non-GAAP net income consists of GAAP net income/(loss), as reported, and adds back acquisition-related deferred revenue adjustments; acquisition-related amortization; stock-based compensation expense; transaction, legal and other costs; non-cash asset and long-term investment impairment charges; non-cash charges to interest expense and other, asset impairment charges; goodwill impairment charges; gain on sale of business, net; and equity in net earnings of unconsolidated investments and the related tax effect of the aforementioned adjustments. Non-GAAP net income also includes a GAAP to non-GAAP tax rate alignment adjustment. Reconciliations to GAAP net income/(loss) are found in Tables 4 and 6 within this press release.
  • Non-GAAP net income attributable to Allscripts Healthcare Solutions, Inc. is a non-GAAP measure and consists of non-GAAP net income, as described above, with an adjustment to reduce non-GAAP net income for the percentage of non-controlling interest outside Allscripts ownership position.
  • Non-GAAP earnings per share consist of non-GAAP net income, as defined above, divided by weighted shares outstanding – diluted during the applicable period.
  • Free cash flow consists of GAAP cash flows provided by operating activities in the applicable period, net of capital expenditures and capitalized software costs, including those incurred by businesses presented as discontinued operations. Reconciliations to GAAP cash flows provided by operating activities are found in Table 7 within this press release.

Acquisition-Related Deferred Revenue Adjustments. Deferred revenue adjustments include acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenue acquired in a business acquisition. The fair value of acquired deferred revenue represents an amount equivalent to the estimated cost plus an appropriate profit margin, to perform services related to the acquiree’s software and product support, which assumes a legal obligation to do so, based on the deferred revenue balances as of the acquisition date. Allscripts adds back acquisition-related deferred revenue adjustments for its non-GAAP financial measures because it believes the inclusion of this amount directly correlates to the underlying performance of Allscripts operations.

Acquisition-Related Amortization. Acquisition-related amortization expense is a non-cash expense arising primarily from the acquisition of intangible assets in connection with acquisitions or investments. Allscripts excludes acquisition-related amortization expense from non-GAAP gross profit, non-GAAP operating income, and non-GAAP net income because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods because of new acquisitions and full amortization of previously acquired intangible assets. Investors should note that the use of these intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation, and the related amortization expense will recur in future periods.

Stock-Based Compensation Expense. Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards. Allscripts excludes stock-based compensation expense from non-GAAP gross profit, non-GAAP operating income, non-GAAP operating expense, non-GAAP net income and Adjusted EBITDA because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods as a result of the timing and valuation of grants of new stock-based awards, including grants in connection with acquisitions. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods, and such expense will recur in future periods.

Asset impairment charges. Asset impairment charges include (i) the write-off of purchased third-party software as a result of our decision to discontinue several software development projects, (ii) the write-off of acquired technology and value assigned to commercial agreements, and (iii) the write-off of the book value of certain fixed assets that resulted from consolidating business functions and data centers.

Goodwill impairment charges. We performed our 2019 goodwill impairment test as of October 1, 2019. We concluded that the carrying value of a business unit in the Provider segment exceeded its fair value as a result of this test. As a result, we recognized a goodwill impairment charge in the fourth quarter of 2019.

Transaction, Legal and Other Costs. Transaction, legal and other costs relate to certain legal proceedings and investigations, consulting, severance, incentive compensation and other charges incurred in connection with activities that are considered not reflective of our core business.

Allscripts excludes transaction, legal and other costs, in whole or in part, from non-GAAP gross profit, non-GAAP operating income, non-GAAP operating expense, non-GAAP net income and Adjusted EBITDA because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods.

Non-Cash Charges to Interest Expense and Other. Non-cash charges to interest expense include the amortization of the fair value of the conversion option embedded in the 1.25 and 0.875 percent Convertible Notes issued by Allscripts during the second quarter of 2013 and fourth quarter of 2019, respectively.

Impairment of Long-Term Investments. Impairment of long-term investments relates to other-than-temporary non-cash impairment charges associated with such investments based on management’s assessment of the likelihood of near-term recovery of the investments’ value.

Gain on sale of business, net. Gain on sale of businesses, net for the year ended December 31, 2018 consists of $177.9 million gain, partly offset by $5.6 million loss, from the divestitures of our OneContent and Strategic Sourcing businesses, respectively, both of which were acquired as part of the EIS transaction during the fourth quarter of 2017.

Equity in Net loss (income) of Unconsolidated Investments. Equity in net loss (income) of unconsolidated investments represents Allscripts share of the equity earnings of our investments in third parties accounted for under the equity method, including the amortization of cost basis adjustments.

Tax Rate Alignment. Tax rate alignment aligns the applicable period’s effective tax rate to the expected annual non-GAAP effective tax rate.

Management also believes that non-GAAP revenue, gross profit, gross margin, operating expense, income from operations, effective income tax rate, net income, earnings per share, Adjusted EBITDA, and free cash flow provide useful supplemental information to management and investors regarding the underlying performance of Allscripts business operations. Acquisition accounting adjustments made in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the business without considering the non-GAAP adjustments provided and discussed herein.

Management also uses this information internally for forecasting and budgeting, as it believes that these measures are indicative of core operating results. In addition, management may use non-GAAP gross profit, operating expense, operating income, net income, earnings per share and/or Adjusted EBITDA to measure achievement under Allscripts stock and cash incentive compensation plans. Note, however, that non-GAAP gross profit, operating income, net income earnings per share and Adjusted EBITDA are performance measures only, and they do not provide any measure of cash flow or liquidity. Allscripts considers free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by the business after capital expenditures and capitalized software costs. Free cash flow provides management and investors a valuable measure to determine the quantity of capital generated that can be deployed to create additional shareholder value by a variety of means. Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Allscripts results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the definitions and reconciliations of non-GAAP financial measures with GAAP financial measures contained within the attached condensed consolidated financial statements.

Investors:

Stephen Shulstein

312-386-6735

stephen.shulstein@allscripts.com

Media:

Concetta Rasiarmos

312-447-2466

concetta.rasiarmos@allscripts.com

Source: Allscripts Healthcare Solutions, Inc.

02/27/2020

Pulse8 Returns to RISE Nashville 2020

CHICAGO–(BUSINESS WIRE)–Feb. 27, 2020–
Pulse8, the cutting-edge healthcare analytics and technology company, is excited to return as a Platinum Sponsor of RISE Nashville 2020 and kick off this event with a valuable Pre-Conference Workshop on What Health Plans and Providers Should Be Seeing at the Crossroads of Better Data and Advanced Analytics.

In its 14th year, the annual RISE Nashville Summit continues to host thought leaders, key stakeholders, and influencers of all levels in the Medicare Advantage, Medicaid, ACA Commercial, ACO markets and maintains its place as the must-attend opportunity to learn about the latest technologies, best practices, and regulatory trends. During Pulse8’s Pre-Conference workshop taking place on March 15th, attendees will hear from Pulse8’s industry experts, as well as notable health plan and provider partners, on topics such as:

  • Value-based Care: Synergizing Advanced Analytics, Technologies, and Interoperability for more successful Risk Adjustment and Quality Outcomes;
  • Reducing Plan and Provider Burden for Better Engagement and Outcomes in a rapidly shifting Healthcare Landscape; and
  • Integrating Risk, Quality, and Pharmacy Opportunities at the Point of Care to improve Clinical and Financial Outcomes

“We are thrilled to sponsor RISE Nashville 2020 and to host our 4th workshop addressing hot topics in the industry today. We look forward to the robust discussion about what your health system and health plan should be achieving from its data and analytics, and how we are the best at making that happen,” says John Criswell, CEO of Pulse8. “Our purpose continues to be eliminating wasteful and unnecessary interventions that deliver no value and this workshop delivers upon our commitment to achieve this objective on how analytics and predictive techniques can improve quality of care.”

Visit Pulse8’s booth to speak with subject matter experts and industry leaders from the team. To schedule a meeting or demo, please call Scott Filiault at 732.570.9095 or email him at Scott.Filiault@pulse8.com.

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

About Pulse8:

Pulse8 is a Healthcare Analytics and Technology Company delivering complete visibility into the efficacy of your Risk Adjustment, Quality, and Pharmacy Benefit Management programs. We enable health plans and providers to eliminate waste and achieve the greatest financial impact in the Medicare Advantage, Medicaid, and ACA Commercial markets as well as with Value-Based Payment models for Medicare. Our advanced analytic methodologies and flexible business intelligence tools offer real-time visibility into member behavior and provider performance. Pulse8’s Illumin8 Active Intelligence™ platform offers a suite of uniquely pragmatic solutions that are powered by our patent-pending Dynamic Intervention Planning to deliver the most cost-effective and appropriate interventions for closing gaps in documentation, coding, and quality. For more company information or to schedule a demo, please Info@Pulse8.com.

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Concetta Rasiarmos

312-447-2466

concetta.rasiarmos@allscripts.com

Source: Allscripts

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Concetta Rasiarmos

312-447-2466

concetta.rasiarmos@allscripts.com

02/25/2020

Allscripts TouchWorks® EHR 20.0 now generally available

New version supports interoperability standards and runs on Chrome

CHICAGO–(BUSINESS WIRE)–Feb. 25, 2020–
Allscripts (NASDAQ: MDRX) has announced Allscripts Touchworks® EHR 20.0, the company’s powerful, scalable and flexible platform designed by clinical and industry experts for large ambulatory practices, is now generally available.

With this new version, TouchWorks EHR runs on Chrome, without the need to install any additional software. TouchWorks 20.0 expands upon Allscripts existing open architecture to support interoperability standards SMART on FHIR and CDS Hooks. This provides clinicians another way to securely embed relevant applications into their core EHR and inject clinical decision support at the point of care.

Developed through a user-centered design process and with modern web conventions, TouchWorks 20.0 features an intuitive design that will require little user training, whether an organization is upgrading from an older version of TouchWorks or is new to the solution. For example, formative user testing shows a 47% increase in SUS (System Usability Scale) scores for the solution’s Charge module.

TouchWorks EHR is a leading EHR platform for large, multi-specialty practices, management services organization (MSO) platforms, and academic and independent delivery networks (IDNs). With its open architecture and configurability, TouchWorks EHR can scale easily and integrate with existing solutions. TouchWorks EHR provides the right solution for ambulatory practices, including teaching and research-oriented practices, to provide improved patient care and to better facilitate population health initiatives.

“The added functionality and expansive benefits of this milestone version of TouchWorks EHR speaks to our commitment to support our valued clients while inviting new organizations to join the Allscripts family,” said Vice President of TouchWorks, Amy Elkins. “With these enhancements, we’re ensuring that the clinicians we serve are equipped with forward-looking innovation to address their patients’ needs today and tomorrow.”

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2020 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Concetta Rasiarmos

312-447-2466

concetta.rasiarmos@allscripts.com

Source: Allscripts

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Concetta Rasiarmos

312-447-2466

concetta.rasiarmos@allscripts.com

02/18/2020

Allscripts and Manorama Infosolutions partner to deliver a Health Information Exchange and population health management services in India and other emerging markets

dbMotion™ Solution to reach 1.4 billion people through strategic partnership

CHICAGO–(BUSINESS WIRE)–Feb. 18, 2020–
Allscripts Healthcare Solutions (NASDAQ: MDRX) today announced its strategic partnership with Manorama Infosolutions, a healthcare IT company located in India, to deliver an integrated Healthcare Management Information System and Health Information Exchange platform. Manorama will Integrate Allscripts interoperability platform, dbMotion Solution with Lifeline Suite of solutions, extending its reach to an additional 1.4 billion people.

Manorama Infosolutions is a pioneer in healthcare IT providing enterprise solutions globally, offering solutions for public health, corporate hospitals and medical centers. Manorama Infosolutions delivers a comprehensive portfolio of healthcare products and services using the Microsoft platform. The partner offers deep expertise in innovative solutions such as electronic medical records, telemedicine, and connected devices such as mobile apps and patient portals, impacting patient safety along with quality of healthcare delivery.

The dbMotion Solution harmonizes data from all disparate clinical and financial source systems to deliver it in a usable way to the point of care in support of clinical decision making and to analytics engines based on organizational needs. The impact of dbMotion has been demonstrated to reduce the cost of care delivery, enables physicians to provide more informed patient care and drives clinical outcomes and improve patient satisfaction and confidence in their care.

“Government bodies responsible for healthcare desire a platform that enables them to collect data, integrate and act on this public ‘health information,’” said Manorama Infosolutions CEO and MD, Mrs. Ashvini Danigond. “By offering the integrated solution of dbMotion, we will enable health policy administrators and authorities to implement and track healthcare policies effectively through the use of population health and central EHRs, as well as empower them to make more informed decisions for safer, more efficient policy implementation.”

“The dbMotion Solution enables healthcare organizations all around the world to access a single record across the continuum, get aggregated data within the native EHR and use multiple, disparate EHR systems,” said Paul M. Black, Chief Executive Officer of Allscripts. “Our partnership with Manorama will further expand the company’s reach to under-served areas in India and other emerging markets, contribute to Allscripts larger reseller strategy and showcase the company’s continued growth internationally.”

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2020 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Source: Allscripts

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Concetta Rasiarmos

312-447-2466

concetta.rasiarmos@allscripts.com

02/14/2020

Allscripts to release fourth-quarter and full-year 2019 financial results March 2

CHICAGO–(BUSINESS WIRE)–Feb. 14, 2020–
Allscripts Healthcare Solutions, Inc. (Nasdaq:MDRX) will report its financial results for the three months and full year ended December 31, 2019, after the close of stock market hours on Monday, March 2nd. Allscripts management plans to host a conference call and webcast to discuss the company’s earnings and other information at 4:30 p.m. Eastern Time that same day.

Fourth-Quarter and Full-Year 2019 Financial Results Call Details

The Allscripts earnings announcement will be distributed immediately after the close of regular stock market hours on March 2, 2020. The announcement will also be available at Allscripts investor relations website.

To listen to the conference call, participants may log onto the Allscripts Investor Relations website. Participants also may access the conference call by dialing (877) 269-7756 or 201-689-7817 and requesting Conference ID # 13699139.

A replay of the call will be available approximately two hours after the conclusion of the call, for a period of four weeks, on the Allscripts investor relations website or by calling (877) 660-6853 or (201) 612-7415 – Conference ID # 13699139.

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2020 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

 

Source: Allscripts

For more information contact:

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Concetta Rasiarmos

312-447-2466

concetta.rasiarmos@allscripts.com

02/12/2020

Memorial Sloan Kettering Cancer Center Extends Allscripts Sunrise™ Agreement

CHICAGO–(BUSINESS WIRE)–Feb. 12, 2020–
Allscripts Healthcare Solutions (NASDAQ: MDRX) today announced that Memorial Sloan Kettering Cancer Center (MSK), has extended its engagement with Allscripts Sunrise™ through 2026.

Allscripts Sunrise is an integrated electronic health record that can connect all aspects of care. As an evidence-based single platform, Sunrise has integrated analytics that can support core care venues across the enterprise.

“The Allscripts Sunrise platform has been a key component in our clinical platform for two decades,” said Memorial Sloan Kettering Cancer Center’s Chief Operating Officer, Kathryn Martin. “We look forward to continued collaboration with the Health IT company, working to meet the needs of our clinicians and, most importantly, our patients.”

“We’re honored to continue our work with Memorial Sloan Kettering Cancer Center, the largest and oldest private cancer center in the world,” said Allscripts CEO Paul Black. “Our more than 20-year relationship has helped many patients within the cancer community receive world-class care and we’re certain that the cancer center’s extension of its Sunrise engagement will be the right fit for its future success.”

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2020 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

 

Source: Allscripts

For more information contact:

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Concetta Rasiarmos

312-447-2466

concetta.rasiarmos@allscripts.com

02/06/2020

Allscripts Sunrise™ Wins Best in KLAS Award

Acute solution named 2020 Best in KLAS – Global Acute Care EMR (Canada)

RICHMOND, British Columbia–(BUSINESS WIRE)–Feb. 6, 2020–
KLAS Research named Allscripts (NASDAQ: MDRX) Sunrise™ as 2020 Best in KLAS – Global Acute Care EMR (Canada). Allscripts Sunrise Acute Care is a clinical solution that provides advanced decision support, such as Computerized Physician Order Entry (CPOE), to help hospital teams improve patient care. According to the 2020 Best in KLAS – Global Acute Care EMR (Canada) report, the solution outpaced competitors in delivering new technology and earning customer loyalty.

“Providers and payers demand better performance, usability, and interoperability from their vendor partners every year,” says Adam Gale, President of KLAS. “Best in KLAS winners set the standard of excellence in their market segment. Earning a Best in KLAS award should both excite and humble the recipients. It serves as a signal to providers that they can expect the best from the winning vendors.”

KLAS Research independently monitors healthcare technology performance through the active participation of users. Healthcare professionals evaluate the software they use, and KLAS Research analyzes and publishes the results in its annual Best in KLAS: Global Software (Non-US) report.

“This Best in KLAS award demonstrates Allscripts Sunrise comprehensive and flexible features that our clients require when facing today’s challenges in delivering complex care models,” said President of Allscripts Global, Alan Fowles. “Allscripts continues to focus on delivering industry leading, highly coordinated service to our clients globally and is proud that Sunrise is helping hospitals and health systems around the globe improve the clinician experience and provide quality patient care.”

Used by healthcare organizations across the globe, Allscripts Sunrise is an integrated electronic patient record that connects all aspects of care, including acute, ambulatory, surgical, radiology and personalized medicine. Built to enable efficient and safe care, Sunrise is a clinician-friendly, evidence-based single platform with advanced analytics that helps deliver true personalized medicine. Sunrise supports all core care venues across the enterprise by delivering a single patient record, and features patient-centric capabilities that can increase access and convenience for the consumer.

Allscripts celebrates this award with our Canadian clients who continue to deliver exceptional care every day.

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

About KLAS

KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers to be heard and counted. Working with thousands of healthcare executives and clinicians, KLAS gathers data on software, services, medical equipment and infrastructure systems to deliver timely reports, trends and statistical overviews. The research directly represents the provider voice and acts as a catalyst for improving supplier performance. KLAS was founded in 1996, and their staff and advisory board average 25 years of healthcare information technology experience. Follow KLAS on Twitter at www.twitter.com/KLASresearch.

© 2020 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Source: Allscripts

For more information contact:

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Concetta Rasiarmos

312-447-2466

concetta.rasiarmos@allscripts.com

Scroll To Top